ABUS vs EVRG · P/E 5.4, rev $6.2M vs P/E 22, rev $5.85B
Arbutus Biopharma Corp (ABUS) versus Evergy, Inc. (EVRG) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Evergy, Inc. (EVRG) is a utilities - regulated electric company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EVRG revenue for 2024-12-31 was $5.85B. Net income was $885.8M. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. EVRG currently screens at market cap $19.10B and trailing P/E 22.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EVRG currently screens at market cap $19.10B and trailing P/E 22.0.
Not investment advice. Open the ABUS and EVRG stock pages for the full models.
Not investment advice.